

1 **Specialty Visits and Real-world Initiation of Cardioprotective Anti-hyperglycemic**
2 **Medications Among US Adults with Type 2 Diabetes**

3 Arash A Nargesi MD MPH¹, Callahan Clark PharmD², Mengni Liu MS³, Abraham Reddy
4 PhD², Samuel Amodeo MS², Rohan Khera MD MS^{3,4}

5 ¹ Department of Internal Medicine, Yale School of Medicine, New Haven, CT

6 ² Optum Labs, Minnetonka, MN

7 ³ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New
8 Haven, CT

9 ⁴ Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School
10 of Medicine, New Haven, CT

11 **Correspondence to:**

12 Rohan Khera, MD, MS

13 195 Church St, 5th Floor, New Haven, CT 06510

14 203-764-5885; rohan.khera@yale.edu; @rohan_khera

15 **Word Count:** 1090

16 **Illustrations:** 2

17 **ABSTRACT**

18 Prescription of sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like
19 peptide-1 receptor agonists (GLP-1RA) among patients with guideline-directed
20 indications remains limited with substantial inter-prescriber variability. In this prospective
21 study of US adults, we used administrative claims database of individuals with type 2
22 diabetes and compelling indications for SGLT-2i and GLP-1RA to evaluate the impact of
23 healthcare visits with certain specialty providers on the initiation of these medications.
24 These specialties included family medicine, internal medicine, cardiology,
25 endocrinology, and nephrology. Overall, 294,988 individuals eligible for SGLT-2i and
26 198,525 for GLP-1RA were identified. In 2019-2020, SGLT-2i and GLP-1RA were
27 initiated in 10.4% and 16.7% of eligible individuals, respectively. After accounting for
28 patient characteristics and comorbidities, healthcare visit with endocrinologists was
29 associated with the highest rate of initiation of either drug across specialties (OR=2.16
30 [2.08-2.24] for SGLT-2i, and 2.76 [2.64-2.88] for GLP-1RA). Healthcare visits with
31 cardiologists and with family medicine and internal medicine physicians were only
32 modestly associated with initiation of SGLT-2i and GLP-1RA. The study highlights the
33 need for broad education for expansion of the use of these medications rather than
34 focus on dedicated specialty clinics.

35 **BACKGROUND**

36 Clinical practice guidelines recommend sodium glucose cotransporter-2 inhibitors
37 (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for individuals with
38 type 2 diabetes (T2D) and high cardiovascular risk. Fewer than 1 in 10 patients with
39 guideline-directed class I indications receive these medications in the US.¹ With
40 substantial prescriber-level variation for SGLT-2i and GLP-1RA prescriptions,² the
41 impact of healthcare visits with specific specialty providers on the use of these
42 medications has not been well characterized. In a prospective nationwide cohort of US
43 adults with compelling indications for SGLT-2i and GLP-1RA use followed for 2 years,
44 we evaluated whether care received from certain clinical specialists portended
45 successful initiation of these essential drugs.

46 **METHODS**

47 We used Optum Lab's de-identified administrative claims data from beneficiaries with
48 Medicare Advantage Part D or commercial insurance representing a mixture of ages
49 and geographical regions from across the US. Individuals 18 years of age or older with
50 T2D and American Diabetes Association and American Heart Association guideline-
51 based comorbidity indication for SGLT-2i or GLP-1RA with 36 months of continuous
52 enrollment from 2018-2020 were included. To ascertain new initiators, the study
53 identified individuals without pharmacy claims for these medications throughout 2018.
54 These individuals were followed from January 2019 through December 2020, with
55 pharmacy claims defining initiation of treatment.

56 Comorbidity-based indications included atherosclerotic cardiovascular disease
57 (ASCVD), heart failure, and diabetic nephropathy for SGLT-2i and ASCVD for GLP-

58 1RA.³ Exclusion criteria were chronic kidney disease stage IV-V, end stage renal
59 disease, and dialysis for SGLT-2i; and medullary thyroid carcinoma and multiple
60 endocrine neoplasia syndrome type-2 for GLP-1RA.

61 The study exposure was one or more visits with clinicians of specific specialties
62 that provide care to patients with T2D. These specialties included family medicine,
63 internal medicine, cardiology, nephrology, and endocrinology. Study outcome was
64 defined as new initiation of SGLT-2i and GLP-1RA.

65 In multivariable logistic regression, we evaluated whether receiving care from a
66 specific clinician group was associated with higher initiation of cardioprotective agents.
67 We adjusted for factors that may portend patient-level differences, including age, sex,
68 neighborhood income, insurance type (Medicare vs Commercial), Charlson comorbidity
69 index (CCI), and frequency of clinical encounters parametrized as tertiles as a surrogate
70 for healthcare needs. For SGLT-2i, indication of use was included in the model. Data
71 were analyzed using R (CRAN-3.4.0) with 2-tailed $p < 0.05$ to define significance.

72 **RESULTS**

73 We identified 294,988 individuals eligible for SGLT-2i and 198,525 for GLP-1RA.
74 Among those eligible for SGLT-2i, 62.5% had at least one encounter with family
75 medicine, 62.0% with internal medicine, 57.2% with cardiology, 21.0% with nephrology,
76 and 14.4% with endocrinology. Among those eligible for GLP-1RA, 61.9% had at least
77 one encounter with family medicine, 62.9% with internal medicine, 64.4% with
78 cardiology, 16.6% with nephrology, and 13.7% with endocrinology (**Table**). Overall,
79 30,707 individuals with an indication for SGLT-2i (10.4%) and 33,311 for GLP-1RA
80 (16.7%) initiated the medication in 2019-2020.

81 In multivariable models adjusted for demographic and comorbidity profiles,
82 healthcare visit with endocrinology was associated with the highest rates of initiation of
83 either drug across specialties (OR=2.16 [2.08-2.24] for SGLT-2i, and 2.76 [2.64-2.88]
84 for GLP-1RA) after accounting for differences in patient characteristics. Healthcare visits
85 with cardiologists and with family medicine and internal medicine physicians were only
86 modestly associated with initiation of SGLT-2i and GLP-1RA (**Figure**). Diabetic
87 nephropathy and nephrology visits were associated with lower initiation rates for SGLT-
88 2i (OR=0.94 [0.90-0.99] and 0.7 [0.67-0.74], respectively), but not GLP-1RA.

89 **DISCUSSION**

90 Individuals receiving care from endocrinologists have 2- to 3-fold higher rates of SGLT-
91 2i and GLP-1RA initiation. In contrast, initiation rates among those receiving care from
92 cardiologists were comparable to those from family medicine and internal medicine
93 providers, and those with nephrologists were substantially lower. The study does not
94 suggest a uniform benefit from specialty vs. general medical care, and highlights a need
95 for broad education, dissemination, and uptake rather than an approach that focuses on
96 dedicated specialty clinics.

97 The strength of the study is the nationwide assessment of patients across age
98 groups. The limitation is a lack of assessment of glycemic control and identifying the
99 exact provider who prescribed the medication for patients visiting more than one
100 specialty clinician. However, the study represents individuals with high cardiovascular
101 risk, all of whom have an indication for these agents, regardless of their glycemic
102 control.

103

104 **FUNDING**

105 The study was funded by Research & Development at UnitedHealth Group, and the
106 authors Callahan Clark, Abraham Reddy, and Samuel Amodeo are full-time employees
107 of the UnitedHealth Group. These authors played an active role in all aspects of the
108 development of the study, including design and conduct of the study; collection,
109 management, analysis, and interpretation of the data; preparation, review, or approval
110 of the manuscript; and decision to submit the manuscript for publication. The study was
111 supported by the National Heart, Lung, and Blood Institute of the National Institutes of
112 Health under award, 1K23HL153775 to Dr. Khera. The funder had no role in the design
113 and conduct of the study; collection, management, analysis, and interpretation of the
114 data; preparation, review, or approval of the manuscript; and decision to submit the
115 manuscript for publication.

116 **DISCLOSURE**

117 Callahan Clark, Abraham Reddy, and Samuel Amodeo are full time employees of
118 UnitedHealth Group and own stock in the company. Rohan Khera is the coinventor of
119 US Provisional Patent Application No. 63/177,117, Methods for neighborhood
120 phenomapping for clinical trials and co-founder of Evidence2Health, a precision health
121 and digital health analytics platform. The remaining authors report no potential conflicts
122 of interest.

123 **DATA AVAILABILITY**

124 The data are proprietary and not available for open sharing due to restrictions on our
125 data use agreement.

126 **REFERENCES**

- 127 1. Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R.
128 Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective
129 Antihyperglycemic Agents in Type 2 Diabetes Mellitus. *J Am Heart Assoc.* Jul 6
130 2021;10(13):e021084. doi:10.1161/JAHA.121.021084
- 131 2. Sangha V, Lipska K, Lin Z, et al. Patterns of Prescribing Sodium-Glucose
132 Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. *Circ*
133 *Cardiovasc Qual Outcomes.* Dec 2021;14(12):e008381.
134 doi:10.1161/CIRCOUTCOMES.121.008381
- 135 3. Introduction: Standards of Medical Care in Diabetes-2021. *Diabetes Care.* Jan
136 2021;44(Suppl 1):S1-S2. doi:10.2337/dc21-Sint
137

138 **Table. Baseline characteristics of individuals with type 2 diabetes and guideline-based**
 139 **indication for SGLT-2i and GLP-1RA.** Data are presented as mean (SD) for age, median
 140 [IQR] for income and frequency of clinical encounters, and number (%) for others. Frequency
 141 of clinical encounters include total number of outpatient visits per year. Abbreviations: SGLT-
 142 2i, sodium glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor
 143 agonist; CCI, Charlson comorbidity index; ASCVD, atherosclerotic cardiovascular disease.

	SGLT-2i	GLP-1RA
Number	294,988	198,525
Age (year)	75.5 (8.6)	75.8 (8.3)
Female	147,131 (49.9%)	91,426 (46.1%)
Income (\$)	52,784 [46,338-62,149]	52,782 [46,338-62,036]
Insurance		
Medicare	175,135 (93.3%)	185,316 (93.3%)
Commercial	19,853 (6.7%)	13,209 (6.7%)
CCI Score	5.1 (2.4)	5.1 (2.6)
ASCVD	202,335 (68.6%)	198,525 (100%)
Heart Failure	66,959 (22.7%)	45,736 (23%)
Diabetic Nephropathy	155,270 (52.6%)	70,149 (35.3%)
Total Annual Clinical Encounter	13 [8-21]	13 [8-21]
Specialty Encounter		
Cardiology	168,811 (57.2%)	128,014 (64.5)
Nephrology	62,058 (21%)	33,044 (16.6%)
Endocrinology	42,490 (14.4%)	27,278 (13.7%)
Family Medicine	184,500 (62.5%)	122,899 (61.9%)
Internal Medicine	183,015 (62%)	124,867 (62.9%)

144

Figure. Multivariable predictors of SGLT-2i and GLP-1RA initiation. Data represent odds ratio for each specialty visit adjustment for age, sex, income, insurance type, Charlson comorbidity index, frequency of clinical visits, other specialty visits, and in case of SGLT-2i indication of use. Abbreviations: SGLT-2i, sodium glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist.

